Aprocitentan

Aprocitentan is the medicine in Tryvio, a tablet. The US label calls it an endothelin receptor antagonist. The label lists, as its indication, the treatment of hypertension, to lower blood pressure, in combination with other blood pressure medicines, in adults whose blood pressure is not adequately controlled on other drugs, and says no controlled trials show that it lowers the risk of heart attacks or strokes. A boxed warning says it is contraindicated during pregnancy because it may cause fetal harm; that risk concerns the unborn child and is recorded separately. The atlas holds no trial results for it.

Also called Tryvio

  • Drug
  • In this atlas

Overview

Technical summary

RxNorm ingredient 2679059; the label UNII MZI81HV01P equals the ingredient's. MeSH has no descriptor for aprocitentan (an exact-label lookup returned an empty list on 2026-11-19). RxClass lists the FDA established pharmacologic class Endothelin Receptor Antagonist, and the label says the same. The atlas class page for endothelin receptor antagonists is not in the corpus yet, so the record files under the medicines front only. The label read is the Idorsia Pharmaceuticals Ltd label for Tryvio, application NDA217686, effective 2026-08-14 in openFDA; it is the only openFDA label returned for the ingredient, and Drugs@FDA lists one application with one product. The adult indication and the boxed warning (recipient: fetal) sit in separate claims and contexts. This page records the label indication, the class, the boxed-warning title and one sentence, and the mechanism sentence only: no trial result and no dose is given.

About this drug

Level
Substance
Mechanism
The label says aprocitentan is an endothelin receptor antagonist that inhibits the binding of endothelin-1 to ET A and ET B receptors.

Claims and evidence

Context Adults with hypertension that is not adequately controlled on other drugs, as described in the US label of Tryvio

Recipient
Recipient not specified
Population
Adult patients with hypertension who are not adequately controlled on other drugs, taking the medicine in combination with other antihypertensive drugs, as the indications section of the label describes them. The passages read give no other age range.
Care setting
Prescription medicine, as described in the US label
Geography
United States (label of the US Food and Drug Administration)
Life stage
Not stated in the label passages read
Gestational age
Not reported
Postnatal age
Not reported
Follow-up
Not applicable (label statement)
Eligibility: 1 inclusion criterion; exclusion criteria not stated
Included
  • Adult patients with hypertension who are not adequately controlled on other drugs, treated in combination with other antihypertensive drugs
Excluded
None stated
  • Description Evidence stage not applicable Certainty not assessed

    The US label of Tryvio (aprocitentan tablets; Idorsia Pharmaceuticals Ltd, application NDA217686; the version dated 2026-08-14 in openFDA) calls the product an endothelin receptor antagonist. It lists the treatment of hypertension, to lower blood pressure, in combination with other antihypertensive drugs, in adult patients who are not adequately controlled on other drugs, as the indication. The label also says there are no controlled trials showing that the medicine reduces the risk of fatal and non-fatal cardiovascular events.

    Applies to Recipient not specified Adults with hypertension that is not adequately controlled on other drugs, as described in the US label of Tryvio

    Certainty method
    Not assessed
    Limitations
    This claim records what one US label says the medicine is indicated for. It is not a finding about how well the medicine works, and the atlas holds no trial result for it. The label also gives a boxed warning about the unborn child, recorded in a separate claim and context. Contraindications, other warnings, interactions, the lactation and pediatric sections and dosing were not recorded. Labels change, and openFDA's own disclaimer says not to rely on it for decisions about medical care.
    Last checked
    2026-11-19
    Next evidence check due
    Not scheduled
    Sources and citations (6)
    1. Background openFDA drug label record for aprocitentan tablets (Tryvio), Idorsia Pharmaceuticals Ltd label: indications, mechanism, class, boxed warning

      Regulator · U.S. Food and Drug Administration (openFDA) · Edition The openFDA drug label record for set id dfe7a2ee-612c-4aba-834a-d68e6b59a0a6 (manufacturer Idorsia Pharmaceuticals Ltd, application NDA217686), returned on 2026-11-19. The label text is dated 2026-08-14 (effective_time). It is the only openFDA label record for this ingredient returned by an openFDA generic-name search on 2026-11-19.

      Locator
      results[0].openfda.application_number[0]
      How it applies
      Application number of the label read, NDA217686.
      Retrieved
      Source effective date
      2026-08-14
      Source state
      Current
      Version fingerprint
      3e34bdb496f14f2febe2052399118a441c9f54a9a7d8f3f9d89ad112eac17818
      Reuse basis
      openFDA data is public domain under a Creative Commons CC0 1.0 Universal dedication, as the openFDA licence page states (fetched 2026-11-19, sha256 7fda0041a24f8d7139a1781d4462ae39643a2ee6f3b0f079946c989a8e1982d2, hash only). Only short passages are quoted. The raw record is committed in the atlas repository.
    2. Background openFDA drug label record for aprocitentan tablets (Tryvio), Idorsia Pharmaceuticals Ltd label: indications, mechanism, class, boxed warning

      Regulator · U.S. Food and Drug Administration (openFDA) · Edition The openFDA drug label record for set id dfe7a2ee-612c-4aba-834a-d68e6b59a0a6 (manufacturer Idorsia Pharmaceuticals Ltd, application NDA217686), returned on 2026-11-19. The label text is dated 2026-08-14 (effective_time). It is the only openFDA label record for this ingredient returned by an openFDA generic-name search on 2026-11-19.

      Locator
      results[0].effective_time
      How it applies
      Effective date of the label text read, 20260814.
      Retrieved
      Source effective date
      2026-08-14
      Source state
      Current
      Version fingerprint
      3e34bdb496f14f2febe2052399118a441c9f54a9a7d8f3f9d89ad112eac17818
      Reuse basis
      openFDA data is public domain under a Creative Commons CC0 1.0 Universal dedication, as the openFDA licence page states (fetched 2026-11-19, sha256 7fda0041a24f8d7139a1781d4462ae39643a2ee6f3b0f079946c989a8e1982d2, hash only). Only short passages are quoted. The raw record is committed in the atlas repository.
    3. Supports openFDA drug label record for aprocitentan tablets (Tryvio), Idorsia Pharmaceuticals Ltd label: indications, mechanism, class, boxed warning

      Regulator · U.S. Food and Drug Administration (openFDA) · Edition The openFDA drug label record for set id dfe7a2ee-612c-4aba-834a-d68e6b59a0a6 (manufacturer Idorsia Pharmaceuticals Ltd, application NDA217686), returned on 2026-11-19. The label text is dated 2026-08-14 (effective_time). It is the only openFDA label record for this ingredient returned by an openFDA generic-name search on 2026-11-19.

      Locator
      results[0].description[0], first sentence
      How it applies
      Label passage quoted in the research quote table (Q-W4K28-APR-LB-04).
      Retrieved
      Source effective date
      2026-08-14
      Source state
      Current
      Version fingerprint
      3e34bdb496f14f2febe2052399118a441c9f54a9a7d8f3f9d89ad112eac17818
      Reuse basis
      openFDA data is public domain under a Creative Commons CC0 1.0 Universal dedication, as the openFDA licence page states (fetched 2026-11-19, sha256 7fda0041a24f8d7139a1781d4462ae39643a2ee6f3b0f079946c989a8e1982d2, hash only). Only short passages are quoted. The raw record is committed in the atlas repository.
    4. Supports openFDA drug label record for aprocitentan tablets (Tryvio), Idorsia Pharmaceuticals Ltd label: indications, mechanism, class, boxed warning

      Regulator · U.S. Food and Drug Administration (openFDA) · Edition The openFDA drug label record for set id dfe7a2ee-612c-4aba-834a-d68e6b59a0a6 (manufacturer Idorsia Pharmaceuticals Ltd, application NDA217686), returned on 2026-11-19. The label text is dated 2026-08-14 (effective_time). It is the only openFDA label record for this ingredient returned by an openFDA generic-name search on 2026-11-19.

      Locator
      results[0].indications_and_usage[0], indication statement
      How it applies
      Label passage quoted in the research quote table (Q-W4K28-APR-LB-05).
      Retrieved
      Source effective date
      2026-08-14
      Source state
      Current
      Version fingerprint
      3e34bdb496f14f2febe2052399118a441c9f54a9a7d8f3f9d89ad112eac17818
      Reuse basis
      openFDA data is public domain under a Creative Commons CC0 1.0 Universal dedication, as the openFDA licence page states (fetched 2026-11-19, sha256 7fda0041a24f8d7139a1781d4462ae39643a2ee6f3b0f079946c989a8e1982d2, hash only). Only short passages are quoted. The raw record is committed in the atlas repository.
    5. Supports openFDA drug label record for aprocitentan tablets (Tryvio), Idorsia Pharmaceuticals Ltd label: indications, mechanism, class, boxed warning

      Regulator · U.S. Food and Drug Administration (openFDA) · Edition The openFDA drug label record for set id dfe7a2ee-612c-4aba-834a-d68e6b59a0a6 (manufacturer Idorsia Pharmaceuticals Ltd, application NDA217686), returned on 2026-11-19. The label text is dated 2026-08-14 (effective_time). It is the only openFDA label record for this ingredient returned by an openFDA generic-name search on 2026-11-19.

      Locator
      results[0].indications_and_usage[0], indication statement, population
      How it applies
      Label passage quoted in the research quote table (Q-W4K28-APR-LB-06).
      Retrieved
      Source effective date
      2026-08-14
      Source state
      Current
      Version fingerprint
      3e34bdb496f14f2febe2052399118a441c9f54a9a7d8f3f9d89ad112eac17818
      Reuse basis
      openFDA data is public domain under a Creative Commons CC0 1.0 Universal dedication, as the openFDA licence page states (fetched 2026-11-19, sha256 7fda0041a24f8d7139a1781d4462ae39643a2ee6f3b0f079946c989a8e1982d2, hash only). Only short passages are quoted. The raw record is committed in the atlas repository.
    6. Supports openFDA drug label record for aprocitentan tablets (Tryvio), Idorsia Pharmaceuticals Ltd label: indications, mechanism, class, boxed warning

      Regulator · U.S. Food and Drug Administration (openFDA) · Edition The openFDA drug label record for set id dfe7a2ee-612c-4aba-834a-d68e6b59a0a6 (manufacturer Idorsia Pharmaceuticals Ltd, application NDA217686), returned on 2026-11-19. The label text is dated 2026-08-14 (effective_time). It is the only openFDA label record for this ingredient returned by an openFDA generic-name search on 2026-11-19.

      Locator
      results[0].indications_and_usage[0], outcomes sentence
      How it applies
      Label passage quoted in the research quote table (Q-W4K28-APR-LB-07).
      Retrieved
      Source effective date
      2026-08-14
      Source state
      Current
      Version fingerprint
      3e34bdb496f14f2febe2052399118a441c9f54a9a7d8f3f9d89ad112eac17818
      Reuse basis
      openFDA data is public domain under a Creative Commons CC0 1.0 Universal dedication, as the openFDA licence page states (fetched 2026-11-19, sha256 7fda0041a24f8d7139a1781d4462ae39643a2ee6f3b0f079946c989a8e1982d2, hash only). Only short passages are quoted. The raw record is committed in the atlas repository.

Context The developing fetus, for a person taking aprocitentan during pregnancy, as described in a US label boxed warning

Recipient
Fetal
Population
The developing fetus when a pregnant person takes the medicine, as the label boxed warning describes the risk. The warning is not about the person who takes the medicine.
Care setting
Prescription medicine, as described in the US label
Geography
United States (label of the US Food and Drug Administration)
Life stage
Fetus during pregnancy; the passage read gives no gestational ages
Gestational age
Not reported
Postnatal age
Not reported
Follow-up
Not applicable (label statement)
Eligibility: 1 inclusion criterion; exclusion criteria not stated
Included
  • The developing fetus when a pregnant person takes the medicine, as the label boxed warning describes the risk. The warning is not about the person who takes the medicine.
Excluded
None stated
  • Safety Evidence stage not applicable Certainty not assessed

    The same US label of Tryvio carries a boxed warning titled embryo-fetal toxicity. It says the medicine is contraindicated for use during pregnancy because it may cause fetal harm if used by pregnant patients.

    Applies to Fetal The developing fetus, for a person taking aprocitentan during pregnancy, as described in a US label boxed warning

    Certainty method
    Not assessed
    Limitations
    This claim records the boxed-warning title and its first statement only. The warning also tells prescribers what to do before, during and after treatment of people who could become pregnant; that instruction is not repeated here. Other warnings, contraindications and interactions were not recorded, and no pregnancy or lactation guidance is given. Labels change, and openFDA's own disclaimer says not to rely on it for decisions about medical care.
    Last checked
    2026-11-19
    Next evidence check due
    Not scheduled
    Sources and citations (4)
    1. Background openFDA drug label record for aprocitentan tablets (Tryvio), Idorsia Pharmaceuticals Ltd label: indications, mechanism, class, boxed warning

      Regulator · U.S. Food and Drug Administration (openFDA) · Edition The openFDA drug label record for set id dfe7a2ee-612c-4aba-834a-d68e6b59a0a6 (manufacturer Idorsia Pharmaceuticals Ltd, application NDA217686), returned on 2026-11-19. The label text is dated 2026-08-14 (effective_time). It is the only openFDA label record for this ingredient returned by an openFDA generic-name search on 2026-11-19.

      Locator
      results[0].openfda.application_number[0]
      How it applies
      Application number of the label read, NDA217686.
      Retrieved
      Source effective date
      2026-08-14
      Source state
      Current
      Version fingerprint
      3e34bdb496f14f2febe2052399118a441c9f54a9a7d8f3f9d89ad112eac17818
      Reuse basis
      openFDA data is public domain under a Creative Commons CC0 1.0 Universal dedication, as the openFDA licence page states (fetched 2026-11-19, sha256 7fda0041a24f8d7139a1781d4462ae39643a2ee6f3b0f079946c989a8e1982d2, hash only). Only short passages are quoted. The raw record is committed in the atlas repository.
    2. Background openFDA drug label record for aprocitentan tablets (Tryvio), Idorsia Pharmaceuticals Ltd label: indications, mechanism, class, boxed warning

      Regulator · U.S. Food and Drug Administration (openFDA) · Edition The openFDA drug label record for set id dfe7a2ee-612c-4aba-834a-d68e6b59a0a6 (manufacturer Idorsia Pharmaceuticals Ltd, application NDA217686), returned on 2026-11-19. The label text is dated 2026-08-14 (effective_time). It is the only openFDA label record for this ingredient returned by an openFDA generic-name search on 2026-11-19.

      Locator
      results[0].effective_time
      How it applies
      Effective date of the label text read, 20260814.
      Retrieved
      Source effective date
      2026-08-14
      Source state
      Current
      Version fingerprint
      3e34bdb496f14f2febe2052399118a441c9f54a9a7d8f3f9d89ad112eac17818
      Reuse basis
      openFDA data is public domain under a Creative Commons CC0 1.0 Universal dedication, as the openFDA licence page states (fetched 2026-11-19, sha256 7fda0041a24f8d7139a1781d4462ae39643a2ee6f3b0f079946c989a8e1982d2, hash only). Only short passages are quoted. The raw record is committed in the atlas repository.
    3. Supports openFDA drug label record for aprocitentan tablets (Tryvio), Idorsia Pharmaceuticals Ltd label: indications, mechanism, class, boxed warning

      Regulator · U.S. Food and Drug Administration (openFDA) · Edition The openFDA drug label record for set id dfe7a2ee-612c-4aba-834a-d68e6b59a0a6 (manufacturer Idorsia Pharmaceuticals Ltd, application NDA217686), returned on 2026-11-19. The label text is dated 2026-08-14 (effective_time). It is the only openFDA label record for this ingredient returned by an openFDA generic-name search on 2026-11-19.

      Locator
      results[0].boxed_warning[0], title
      How it applies
      Label passage quoted in the research quote table (Q-W4K28-APR-LB-09).
      Retrieved
      Source effective date
      2026-08-14
      Source state
      Current
      Version fingerprint
      3e34bdb496f14f2febe2052399118a441c9f54a9a7d8f3f9d89ad112eac17818
      Reuse basis
      openFDA data is public domain under a Creative Commons CC0 1.0 Universal dedication, as the openFDA licence page states (fetched 2026-11-19, sha256 7fda0041a24f8d7139a1781d4462ae39643a2ee6f3b0f079946c989a8e1982d2, hash only). Only short passages are quoted. The raw record is committed in the atlas repository.
    4. Supports openFDA drug label record for aprocitentan tablets (Tryvio), Idorsia Pharmaceuticals Ltd label: indications, mechanism, class, boxed warning

      Regulator · U.S. Food and Drug Administration (openFDA) · Edition The openFDA drug label record for set id dfe7a2ee-612c-4aba-834a-d68e6b59a0a6 (manufacturer Idorsia Pharmaceuticals Ltd, application NDA217686), returned on 2026-11-19. The label text is dated 2026-08-14 (effective_time). It is the only openFDA label record for this ingredient returned by an openFDA generic-name search on 2026-11-19.

      Locator
      results[0].boxed_warning[0], first sentence
      How it applies
      Label passage quoted in the research quote table (Q-W4K28-APR-LB-10).
      Retrieved
      Source effective date
      2026-08-14
      Source state
      Current
      Version fingerprint
      3e34bdb496f14f2febe2052399118a441c9f54a9a7d8f3f9d89ad112eac17818
      Reuse basis
      openFDA data is public domain under a Creative Commons CC0 1.0 Universal dedication, as the openFDA licence page states (fetched 2026-11-19, sha256 7fda0041a24f8d7139a1781d4462ae39643a2ee6f3b0f079946c989a8e1982d2, hash only). Only short passages are quoted. The raw record is committed in the atlas repository.

Pregnancy, lactation and children

The claims about this drug whose clinical context is a pregnancy, breastfeeding or a newborn, infant or child, grouped by that context. Each claim is also in Claims and evidence. A group with no claim is not shown, and an empty group does not mean the medicine is safe or unsafe there.

In pregnancy 1

Claims whose context is a pregnancy or a fetus.

  • Safety Evidence stage not applicable Certainty not assessed

    The same US label of Tryvio carries a boxed warning titled embryo-fetal toxicity. It says the medicine is contraindicated for use during pregnancy because it may cause fetal harm if used by pregnant patients.

    Applies to Fetal The developing fetus, for a person taking aprocitentan during pregnancy, as described in a US label boxed warning

    Population, setting and follow-up
    • The developing fetus when a pregnant person takes the medicine, as the label boxed warning describes the risk. The warning is not about the person who takes the medicine.
    • Prescription medicine, as described in the US label
    • United States (label of the US Food and Drug Administration)
    • Fetus during pregnancy; the passage read gives no gestational ages
    • Gestational age Not reported
    • Postnatal age Not reported
    Follow-up Not applicable (label statement)
    Certainty method
    Not assessed
    Limitations
    This claim records the boxed-warning title and its first statement only. The warning also tells prescribers what to do before, during and after treatment of people who could become pregnant; that instruction is not repeated here. Other warnings, contraindications and interactions were not recorded, and no pregnancy or lactation guidance is given. Labels change, and openFDA's own disclaimer says not to rely on it for decisions about medical care.
    Last checked
    2026-11-19
    Next evidence check due
    Not scheduled
    Sources and citations (4)
    1. Background openFDA drug label record for aprocitentan tablets (Tryvio), Idorsia Pharmaceuticals Ltd label: indications, mechanism, class, boxed warning

      Regulator · U.S. Food and Drug Administration (openFDA) · Edition The openFDA drug label record for set id dfe7a2ee-612c-4aba-834a-d68e6b59a0a6 (manufacturer Idorsia Pharmaceuticals Ltd, application NDA217686), returned on 2026-11-19. The label text is dated 2026-08-14 (effective_time). It is the only openFDA label record for this ingredient returned by an openFDA generic-name search on 2026-11-19.

      Locator
      results[0].openfda.application_number[0]
      How it applies
      Application number of the label read, NDA217686.
      Retrieved
      Source effective date
      2026-08-14
      Source state
      Current
      Version fingerprint
      3e34bdb496f14f2febe2052399118a441c9f54a9a7d8f3f9d89ad112eac17818
      Reuse basis
      openFDA data is public domain under a Creative Commons CC0 1.0 Universal dedication, as the openFDA licence page states (fetched 2026-11-19, sha256 7fda0041a24f8d7139a1781d4462ae39643a2ee6f3b0f079946c989a8e1982d2, hash only). Only short passages are quoted. The raw record is committed in the atlas repository.
    2. Background openFDA drug label record for aprocitentan tablets (Tryvio), Idorsia Pharmaceuticals Ltd label: indications, mechanism, class, boxed warning

      Regulator · U.S. Food and Drug Administration (openFDA) · Edition The openFDA drug label record for set id dfe7a2ee-612c-4aba-834a-d68e6b59a0a6 (manufacturer Idorsia Pharmaceuticals Ltd, application NDA217686), returned on 2026-11-19. The label text is dated 2026-08-14 (effective_time). It is the only openFDA label record for this ingredient returned by an openFDA generic-name search on 2026-11-19.

      Locator
      results[0].effective_time
      How it applies
      Effective date of the label text read, 20260814.
      Retrieved
      Source effective date
      2026-08-14
      Source state
      Current
      Version fingerprint
      3e34bdb496f14f2febe2052399118a441c9f54a9a7d8f3f9d89ad112eac17818
      Reuse basis
      openFDA data is public domain under a Creative Commons CC0 1.0 Universal dedication, as the openFDA licence page states (fetched 2026-11-19, sha256 7fda0041a24f8d7139a1781d4462ae39643a2ee6f3b0f079946c989a8e1982d2, hash only). Only short passages are quoted. The raw record is committed in the atlas repository.
    3. Supports openFDA drug label record for aprocitentan tablets (Tryvio), Idorsia Pharmaceuticals Ltd label: indications, mechanism, class, boxed warning

      Regulator · U.S. Food and Drug Administration (openFDA) · Edition The openFDA drug label record for set id dfe7a2ee-612c-4aba-834a-d68e6b59a0a6 (manufacturer Idorsia Pharmaceuticals Ltd, application NDA217686), returned on 2026-11-19. The label text is dated 2026-08-14 (effective_time). It is the only openFDA label record for this ingredient returned by an openFDA generic-name search on 2026-11-19.

      Locator
      results[0].boxed_warning[0], title
      How it applies
      Label passage quoted in the research quote table (Q-W4K28-APR-LB-09).
      Retrieved
      Source effective date
      2026-08-14
      Source state
      Current
      Version fingerprint
      3e34bdb496f14f2febe2052399118a441c9f54a9a7d8f3f9d89ad112eac17818
      Reuse basis
      openFDA data is public domain under a Creative Commons CC0 1.0 Universal dedication, as the openFDA licence page states (fetched 2026-11-19, sha256 7fda0041a24f8d7139a1781d4462ae39643a2ee6f3b0f079946c989a8e1982d2, hash only). Only short passages are quoted. The raw record is committed in the atlas repository.
    4. Supports openFDA drug label record for aprocitentan tablets (Tryvio), Idorsia Pharmaceuticals Ltd label: indications, mechanism, class, boxed warning

      Regulator · U.S. Food and Drug Administration (openFDA) · Edition The openFDA drug label record for set id dfe7a2ee-612c-4aba-834a-d68e6b59a0a6 (manufacturer Idorsia Pharmaceuticals Ltd, application NDA217686), returned on 2026-11-19. The label text is dated 2026-08-14 (effective_time). It is the only openFDA label record for this ingredient returned by an openFDA generic-name search on 2026-11-19.

      Locator
      results[0].boxed_warning[0], first sentence
      How it applies
      Label passage quoted in the research quote table (Q-W4K28-APR-LB-10).
      Retrieved
      Source effective date
      2026-08-14
      Source state
      Current
      Version fingerprint
      3e34bdb496f14f2febe2052399118a441c9f54a9a7d8f3f9d89ad112eac17818
      Reuse basis
      openFDA data is public domain under a Creative Commons CC0 1.0 Universal dedication, as the openFDA licence page states (fetched 2026-11-19, sha256 7fda0041a24f8d7139a1781d4462ae39643a2ee6f3b0f079946c989a8e1982d2, hash only). Only short passages are quoted. The raw record is committed in the atlas repository.

Clinical links

Each link reports what one cited claim says about one population. "Evaluated for" means studied, not shown to work. These links do not show that anything is effective or right for you.

Record details

Record id
cardio:aprocitentan
Content hash
c495249777c7144244fa3a16ceee735712d1722cd0ba89328df67117a3159e10